New Study Published in JCO Precision Oncology Shows Myriad G

New Study Published in JCO Precision Oncology Shows Myriad Genetics' Prolaris Test Can Predict Benefit of Hormone Therapy Treatment in Men with Localized Prostate Cancer

Myriad’s Prolaris Test is the only biomarker test to quantify the benefits of adding androgen deprivation therapy to radiation therapy1 SALT LAKE CITY, May 16, 2024 -- Myriad Genetics, Inc. , a...

Related Keywords

United States , American , Dale Muzzey , Matt Scalo , Glenn Farrell , American Society Of Clinical Oncology , Nasdaq , University Of Utah , Huntsman Cancer Institute , International Journal Of Radiation Oncology , Exchange Commission , Genetics Inc , Prolaris Test , Clinical Oncology , Annual Conference , Jonathan Tward , Prostate Cancer Prognostic Test , Prostate Cancer Prognostic , Harbor Statement , Private Securities Litigation Reform Act , Annual Report , Quarterly Reports , Current Reports , Radiation Oncology , Markets ,